About Cabozantinib S-Malate API
Therapeutic CategoryAnti-Cancer/ Oncology-es
CAS Number
1140909-48-3
API Technology
Synthetic
Dose Form
Oral Solid/Capsules
Dr Reddy's Development Status
Available
Available Regulatory Filing
USDMF, Brazil DMF, Korea DMF
Mechanism of Action
In vitro biochemical and/or cellular assays have shown that cabozantinib inhibits the tyrosine kinase activity of RET, MET, VEGFR-1, -2 and -3, KIT, TRKB, FLT-3, AXL, ROS1, TYRO3, MER, and TIE-2. These receptor tyrosine kinases are involved in both normal cellular function and pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, drug resistance, and maintenance of the tumor microenvironment.
Indication
COMETRIQ is a kinase inhibitor indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC).
Related APIs
Acalabrutinib
Anti-Cancer/ Oncology-es
Enzalutamide-es
Anti-Cancer/ Oncology-es
Request for Quotation
Get in touch with us by filling out the form below. Our team will reach out to you shortly!